Based on the ReShape Lifesciences Inc stock forecast from 0 analysts, the average analyst target price for ReShape Lifesciences Inc is not available over the next 12 months. ReShape Lifesciences Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of ReShape Lifesciences Inc is Slightly Bearish, which is based on 3 positive signals and 5 negative signals. At the last closing, ReShape Lifesciences Inc’s stock price was USD 0.36. ReShape Lifesciences Inc’s stock price has changed by +6.14% over the past week, -42.92% over the past month and -96.12% over the last year.
Past 12 monthsNext 12 months
No recent analyst target price found for ReShape Lifesciences Inc
No recent average analyst rating found for ReShape Lifesciences Inc
Company Overview ReShape Lifesciences Inc
ReShape Lifesciences Inc. provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; Lap-Band 2.0 System, an adjustable postoperatively to increase or decrease the pressure to the band in order to optimize an individual's comfort and therapy effectiveness; and ReShape Calibration Tubes, that fits the lesser curvature of the stomach to reach the pylorus. It is involved in developing ReShape Obalon Balloon System, consists of a swallowable capsule that tracks and displays the location of the balloon during placement; and ReShape Diabetes Bloc-Stim Neuromodulation (DBSN) device, a technology that is in development for the treatment of type 2 diabetes mellitus. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in Irvine, California. Read Less
ReShape Lifesciences Inc. provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of sever...Read More
Frequently Asked Questions About ReShape Lifesciences Inc (RSLS) Stock
Stock Target Advisor's fundamental analysis for ReShape Lifesciences Inc's stock is Slightly Bearish.
Unfortunately we do not have enough data on RSLS's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on RSLS's stock to indicate what its average analyst target is.
RSLS stock's Price/Earning ratio is 0.07.
Our analysis grades RSLS stock's Price / Earning ratio at B+. This means that RSLS stock's Price/Earning ratio is above 12% of the stocks in the Medical Devices sector in the NSD exchange.
Based on this RSLS may be undervalued for its sector.
The last closing price of RSLS's stock was USD 0.36.
The most recent market capitalization for RSLS is USD 5.21M.
Unfortunately we do not have enough analyst data on RSLS's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains ReShape Lifesciences Inc's stock.
As per our most recent records ReShape Lifesciences Inc has 0 Employees.
ReShape Lifesciences Inc's registered address is 18 Technology Drive, Irvine, CA, United States, 92618.
You can get more information about it from ReShape Lifesciences Inc's website at https://www.reshapelifesciences.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
Underpriced compared to earnings
The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
What not to like
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Frequently Asked Questions About ReShape Lifesciences Inc (RSLS) Stock
Stock Target Advisor's fundamental analysis for ReShape Lifesciences Inc's stock is Slightly Bearish.
Unfortunately we do not have enough data on RSLS's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on RSLS's stock to indicate what its average analyst target is.
RSLS stock's Price/Earning ratio is 0.07.
Our analysis grades RSLS stock's Price / Earning ratio at B+. This means that RSLS stock's Price/Earning ratio is above 12% of the stocks in the Medical Devices sector in the NSD exchange.
Based on this RSLS may be undervalued for its sector.
The last closing price of RSLS's stock was USD 0.36.
The most recent market capitalization for RSLS is USD 5.21M.
Unfortunately we do not have enough analyst data on RSLS's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains ReShape Lifesciences Inc's stock.
As per our most recent records ReShape Lifesciences Inc has 0 Employees.
ReShape Lifesciences Inc's registered address is 18 Technology Drive, Irvine, CA, United States, 92618.
You can get more information about it from ReShape Lifesciences Inc's website at https://www.reshapelifesciences.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for RSLS !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
